To study the interaction between insulin secretion and insulin action in maintaining glucose homeostasis, we induced experimental insulin resistance in eight normal baboons, in six baboons treated with 40 mg/kg streptozocin 
Introduction
Investigation of the interaction between insulin secretion and insulin action in maintaining glucose homeostasis is fundamental to understanding the pathophysiology of many types of diabetes mellitus. Non-insulin-dependent diabetes (NIDDM)l is a heterogenous disorder involving defects in both insulin secretion and insulin action (1) . In insulin-dependent diabetes (IDDM) the acute presentation of hyperglycemia usually occurs when increased insulin resistance, intercurrent illness, or puberty are superimposed on subclinical B cell dysfunction.
We wished to test the hypothesis that, whereas normal pancreatic islets are able to adapt to periods of insulin resistance, those with B cell dysfunction may be unable to increase insulin secretion sufficiently to maintain normoglycemia. As a model for graded B cell dysfunction, we have used streptozocin (STZ)-treated adolescent baboons (2) . We have previously shown that, at low doses of STZ, the changes in pancreatic B cell function in these animals are similar to those seen in nondiabetic first-degree relatives ofIDDM patients during the preclinical period of IDDM (3, 4) . We have also shown that higher doses of STZ induce clinical states of non-insulin-requiring or insulin-requiring diabetes, and that the degree of B cell dysfunction measured in vivo within 3 d of sacrifice correlates closely with the quantitative estimates of overall B cell mass and pancreatic insulin content measured in the same animals (5) .
In determining whether normal or STZ-treated animals are capable of adapting to periods of insulin resistance, it is necessary to choose an agent that causes a reversible reduction in peripheral insulin action without having direct effects on the pancreatic B cell. Nicotinic acid (NA), the B group vitamin used in long-term treatment of some of the hyperlipidemic syndromes, fulfills these requirements. Acutely (within a few hours) NA lowers plasma free fatty acid levels (6-9) resulting in improved insulin action (10) (11) (12) . However, during prolonged administration of NA (several days) free fatty acid levels are increased (13) . Since the increased availability of free fatty acids markedly impairs glucose utilization in muscle and other tissues (14) (15) (16) , this is the likely explanation for the insulin resistance associated with long-term NA treatment (17) (18) (19) (20) (21) . Treatment of normal men with 2 wk of oral NA (up to 2 g/d) was associated with a twofold increase in basal and stimulated insulin levels and a profound reduction in insulin sensitivity (21) . That these changes are not due to direct stimulation ofthe islets by NA has been shown both in perfusion studies of rat islets (22) and in pancreatic rat slices (23) where NA, even in high concentrations, both under basal conditions and during maximal stimulation by glucose, glucagon, or theophylline, did not enhance insulin secretion.
We have therefore determined the effect of prolonged NA infusion on insulin sensitivity, pancreatic B cell function, fasting, and postprandial glycemia in normal adolescent baboons and in those with STZ-induced subclinical B cell dysfunction.
Methods Animals
These studies were carried out on conscious adolescent male baboons (Papio cyanocephalus/anubis), weighing 8-14 kg, which were adapted to living in primate tethers. Silastic catheters, permanently implanted in the vena cava through either the jugular or femoral vein were kept patent by a continuous infusion of 150 mmol/liter NaCl and 5 U/ml heparin at the rate of 80-100 ml/24 h. At least 7 d ofrecovery time after catheter implantation were allowed before initiation ofthe studies. The catheters extended outside the cages, allowing frequent blood sampling as well as infusion of test substances without disturbing the animals. Except for the day of study, animals were fed two equal meals at 0800 and 1300 hours. The study was approved by the University ofWashington Regional Primate Center's Experimental Studies Review Committee.
Materials
STZ and NA were obtained from Sigma Chemical Co., St. Louis, MO. NA was prepared as a 0.1% solution. Arginine hydrochloride was obtained from Cutter Laboratories, Sacramento, CA, prepared at a 10% solution. Somatostatin was obtained from Bachem Inc., Torrance, CA.
STZ treatment
STZ was given in the fasting state as an intravenous injection. A total of 10 animals were used as outlined in Table I . Six animals received a single dose of 40 mg/kg (STZ-40). Six animals received two additional doses of 80 mg/kg, separated by at least 1 wk, giving a cumulative dose of 200 mg/kg (STZ-200) for these animals. There were eight normal, six STZ-40, and six STZ-200 animals. There were no significant differences in weight among the groups. All experiments were performed at least 1 wk after the last dose of STZ. 
B cellfunction tests
These tests were carried out after an 18-h overnight fast. Samples were drawn into tubes containing EDTA and Trasylol, placed on ice, and centrifuged within 10 min. Arginine stimulation, both at basal glucose and during hyperglycemic clamp, glucose stimulation, and measurement of insulin sensitivity were performed. All studies were carried out on a single day with glucose stimulation and insulin sensitivity measurements obtained between the basal arginine stimulation and the hyperglycemic clamp. Plasma was then frozen until assayed for immunoreactive insulin. At the end of the study, the red cells were resuspended in 150 mmol/liter NaCl and reinfused into the animal. Symbols: +, the animal was studied at this stage; -, the animal was not studied at this stage.
Arginine stimulation. Insulin secretory responses to intravenous arginine were measured at two different plasma glucose levels. At each level three prestimulus blood samples were obtained 10 min, 5 min, and immediately before administration ofarginine. A dose of0.07 g/kg 10% arginine hydrochloride was administered intravenously in 30 s, the beginning of which was designated time zero. Blood samples were obtained 2,3,4, and 5 min after arginine administration. 3 h later (after the intravenous glucose tolerance test; see below) a variable rate infusion of 50% dextrose was delivered by a syringe pump (model 355, Sage Instruments, Cambridge, MA) in order to raise and maintain the plasma glucose level at -14.0 mmol/liter. Blood samples (0.5 ml) were obtained every 3-5 min for plasma glucose measurement, and based on these values the glucose infusion rate was adjusted. 40 min after commencing the hyperglycemic clamp, a second arginine pulse (0.07 g/kg) was given, and the insulin response was measured as before.
Insulin sensitivity testing. A modified intravenous glucose tolerance test was performed. Blood samples were obtained 10,5, and 2 min before glucose injection. Immediately after this sample was taken, an intravenous bolus of 200 fig somatostatin was given, followed at time zero by a bolus of 0.3 g/kg 50% dextrose. Further blood samples were Analytical methods. Plasma insulin was assayed by a modification of the double-antibody method of Morgan and Lazarow (26) . Plasma glucose was measured using a glucose analyzer (Beckman Instruments, Inc., Palo Alto, CA). All samples from an individual study were analyzed in duplicate in a single assay. Glycosylated hemoglobin (HbA1c) was measured using a sensitive calorimetric thiobarbituric acid method (27) .
Calculations and statistical analysis. Fasting plasma glucose and insulin were calculated as the mean ofthe three samples before the first arginine injection. The acute insulin response to glucose (AIRO.1,,) was calculated as the mean of the poststimulus samples obtained at 2, 3, 4, 5, 6, 8, and 10 min after the intravenous glucose injection minus the mean of the three prestimulus samples. The acute insulin response to arginine at fasting plasma glucose (AIRY.) was calculated as the mean of the poststimulus samples obtained at 2, 3, 4, and 5 min minus the mean of the three prestimulus samples. Pancreatic B cell function. In the normal animals treated with NA, fasting insulin (H) increased about twofold (Table  II) . AIRarg at basal glucose increased from 880± 190 to 1,730±488 pM (P < 0.07) (Fig. 2 , left, upper panel) and also during hyperglycemia clamp of -14 mM, from 2,769±582 to 5,106±1044 pM (P < 0.03), as illustrated in Fig. 3 , top panel.
The slope ofglucose potentiation of AIRI, (AAIR/AG) therefore increased from 191±41 to 361±85 pMi5s -mMglucj1, P < 0.05, (Table II and Fig. 3, upper panel) . AIRfuc in the normal animals increased from 902±108 to 1,703±408 pM during NA infusion (P < 0.04) (Table II and Fig. 2, right, upper panel) .
In the STZ-40 animals all ofthe measures ofB cell function before NA infusion were reduced by about a third but none were significantly different from those of the normal animals before NA infusion. During NA infusion, fasting insulin and AIR. at basal glucose increased significantly (Table II and Fig (Fig. 3, middle panel) , such that AAIR.,JAG remained unchanged (Table II) . AIR.eUC did show a compensatory increase in STZ-40 animals from 602±143 to 1,173±322, P < 0.05, (Table II and Fig. 2, right, 46 In SI, r = 0.66, P < 0.001). In Fig. 4 the curved lines show the mean± 1 SD for these normal animals and provide a setting in which to evaluate the changes seen in normal and STZ-40 animals during NA treatment. Both groups showed an appropriate increase in AI~tj, as SI fell, such that they remained within the expected normal range (upperpanel, Fig. 4) . However, although the normal animals showed an appropriate compensatory increase in AAIR,/AG to the reduction in SI STZ-40 animals failed to do so, thereby falling outside the expected normal range (lower panel, Fig. 4) .
The effects of STZ in reducing insulin secretion is evident over all three groups before NA, using the Kruskal-Wallis test.
Reduction in AIRarg (P < 0.02), AIRglUC (P < 0.002), and AAIRIJ/AG (P < 0.002) were highly significant. Comparing STZ-200 animals with normals using the Mann-Whitney Utest, the fasting insulin, AIR.UC, AIR., and AAIRr/.AG before NA were significantly lower than in normal animals before NA (Table II, P < 0.05). During NA infusion there were slight, but statistically insignificant increases in fasting insulin and AIR., (Table II and Fig. 2, left, lowerpanel) . In contrast, AIR.
during hyperglycemic clamp showed a slight but significant decrease during NA infusion from 360±144 to 276±132 pM (P < 0.05) such that AAIR,,/AG became negative (Table II, and Fig. 3, lower panel) . After intravenous glucose there was also a paradoxical decrement in insulin secretion during NA infusion (Fig. 2, right, lower panel) . In STZ-200 animals before NA, insulin rose from 96± 12 pM before intravenous glucose to remain elevated at -200 pM from 2 to 6 min. In STZ-200 animals during NA, basal insulin was 168±48 pM before glu- 'cI 10 15 20 Glucose ( mM ) (25) and allows measurement of insulin secretion and insulin sensitivity on the same day. We have shown previously, both in normal humans (3) and baboons (2) , that there is an inverse correlation between insulin secretion and insulin sensitivity such that changes in either one can only be fully appreciated when considered in relation to the other (3, 4) . The baboons in this study showed a profound reduction in insulin sensitivity after 2-3 wk of NA treatment comparable to that seen in human adults (21) . Fasting and stimulated insulin levels increased two-to threefold to compensate for the insulin resistance, but stayed within the normal range for animals of that degree of insulin sensitivity (Fig. 4) . (2, 33) . Nonenzymatic glycosylation of hemoglobin in mammals is determined by three major variables: mean plasma glucose concentration, red cell life span and red cell permeability (33) . Since baboons have a higher red cell permeability than humans (33) , and a red cell life span of 45 d compared with 120 d for human (34) gests that B cell adaptation is complete in these animals and that even insulin resistance of this severity is not sufficient to cause hyperglycemia in the presence of normal B cell function.
In STZ-40 animals where AIRV., adaptation was intact but AAIRarg/AG adaptation was markedly impaired, fasting plasma glucose was still maintained during NA treatment but HbAlC rose suggesting postprandial hyperglycemia. This suggests that the physiological importance ofthe glucose potentiation slope (AAIR.,g/AG) is to enhance insulin secretion postprandially when not only glucose but amino acids and other substrate secretagogues are raised in the blood perfusing the islets. Streptozocin treatment causes a reduction in overall B cell mass (5), reducing overall secretory capacity such that the postprandial response is inadequate and glucose levels remain high. The STZ-200 animals had a more severe B cell lesion as evidenced by inadequate adaptive changes ofboth AAIR,,/AG and AIR,,, These animals developed overt diabetes, during the period of induced insulin resistance, which resolved after NA treatment was discontinued (Fig. 5) . These data therefore suggest that, in the presence of significant insulin resistance, the degree of hyperglycemia which develops is proportional to the degree of B cell dysfunction and the ability to compensate for increased demand. Pascoe and Storlein (35) have recently shown that in STZ-treated rats, hyperglycemia only developed when insulin resistance (induced by eating a high fat diet) was superimposed on B-cell dysfunction.
One last finding is worthy of comment. It has been suggested that hyperglycemia itself impairs B cell function (36) , and a paradoxical inhibition of insulin secretion after intravenous administration of glucose has been observed in some humans with NIDDM (37) (38) (39) . Our data from STZ-200 animals during NA infusion support this concept. While normoglycemic, these animals showed an increase in insulin secretion after intravenous glucose, but when NA-induced insulin resistance and inadequate B cell adaptation resulted in hyperglycemia (Fig. 5) , insulin secretion after intravenous glucose actually declined. In our study the nadir occurred at 4 min and had returned to basal by 10 min. Metz et al. (39) using a similar protocol in normal humans and patients with NIDDM found the nadir at 5-10 min with return to baseline by 15 min. These data, and those of our study therefore suggest that, in the presence of a B cell lesion, hyperglycemia exacerbates the degree of B cell dysfunction.
In summary, the present findings demonstrate clearly the relative contributions of pancreatic B cell dysfunction and peripheral insulin resistance to the development of hyperglycemia and show that hyperglycemia itself can further impair B cell function. These data therefore improve understanding of several clinical situations in both NIDDM and IDDM. In NIDDM significant improvements in both insulin action and insulin secretion have been induced by weight reduction or when hyperglycemia is reduced by insulin therapy (39) (40) (41) (42) (43) . These improvements are maintained for 2 wk after withdrawal of insulin therapy (42) .
The acute presentation of IDDM is often due to an intercurrent event which causes insulin resistance to develop in someone with subclinical B cell dysfunction. Because B cell compensation is incomplete, hyperglycemia develops. Insulin therapy may improve the situation in several ways. Exogenous insulin treatment may "rest" the remaining B cells, which may make them less vulnerable to further autoimmune destruction and allow them to recover (44) . Another mechanism by which improved glycemia may occur during the honeymoon period could be because insulin treatment improves insulin sensitivity (45, 46) .
Our data also have implications for the treatment ofindividuals during the preclinical period of IDDM. Various agents have been suggested for the prevention of IDDM (47) . Some of these, like corticosteroids, not only cause decreased insulin sensitivity, but also directly inhibit B cell function (48) (49) (50) . Cyclosporine has been shown, in dogs, to cause an inhibition ofinsulin secretion which does not reverse completely on stopping the drug (51) . A study of cyclosporine treatment in humans with multiple sclerosis showed no effect on glucose homeostasis and insulin secretion after 1 yr (52) 
